Levomentis

Levomepromazine, the active ingredient in Levomentis, is a phenothiazine low‑potency typical antipsychotic presented as an oral formulation for oral use. It treats schizophrenia, severe agitation, nausea and vomiting, and is employed in palliative care to control distressing symptoms.

GNH USA supplies Levomentis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Clients benefit from comprehensive logistics support, including documentation, customs clearance and temperature‑controlled transport where required.

Levomepromazine is a low‑potency phenothiazine antipsychotic used across several clinical pathways.

- Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations and thought disorder. - Severe agitation: calms extreme restlessness and aggressive behavior in acute settings. - Nausea and vomiting: blocks central emetic pathways to control chemotherapy‑induced or postoperative emesis. - Palliative care: alleviates distressing symptoms including refractory nausea, pain‑related anxiety and insomnia.

Levomepromazine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation - Dry mouth - Constipation - Orthostatic hypotension - Blurred vision - Weight gain

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension - Cardiac arrhythmias (including QT prolongation) - Agranulocytosis - Seizures

When prescribing Levomepromazine, clinicians should observe several precautionary measures to minimise risk.

- Dose titration: adjust gradually under medical supervision. - Cardiovascular monitoring: watch for orthostatic hypotension and arrhythmias. - CNS effects: monitor for excessive sedation or confusion. - Anticholinergic load: be cautious in elderly patients prone to urinary retention or constipation. - Pregnancy and lactation: use only if potential benefits outweigh potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Levomepromazine can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Other CNS depressants: may cause profound sedation or respiratory depression. - Antihypertensives: additive hypotensive effect increasing risk of fainting. - Anticholinergic drugs: increase anticholinergic burden leading to severe dry mouth, constipation or urinary retention. - QT‑prolonging agents: raise risk of cardiac arrhythmia. - MAO inhibitors: may precipitate severe hypotension.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase risk of serotonin syndrome. - Lithium: may enhance neurotoxic effects. - Alcohol: enhances sedative effect and impairs coordination. - CYP450 inhibitors or inducers: may alter plasma concentrations of levomepromazine.